Compare Novo Nordisk A/S (NVO) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Novo Nordisk A/S trades at $38.38 (market cap $165.31B), while YieldMax Universe Fund of Option Income ETFs trades at $7.59 (market cap $364M). The key difference: Novo Nordisk A/S is far larger — about 454.1× YieldMax Universe Fund of Option Income ETFs's market cap, and Novo Nordisk A/S pays a 4.71% dividend while YieldMax Universe Fund of Option Income ETFs pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and YieldMax Universe Fund of Option Income ETFs for 55 Days on average.
| NVO | YMAX | |
|---|---|---|
Market Cap | $165.31B | $364M |
Volume | 11,432,838 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $12.98 |
52-Week Low | $35.29 | $7.27 |
Typical Hold Time | 116 Days | 55 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
YMAX trades at $7.53, down 1.83% on the day, with a bearish technical signal from moving averages. The ETF maintains weekly dividend distributions but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues, though the fund's structure as a fund-of-funds adds additional cost layers that impact returns.
The outlook remains cautious due to structural concerns and persistent share price decline despite high yield. Investment opportunity exists for income-focused investors willing to accept principal erosion risks, while the primary risk involves unsustainable distribution policy and compounding fees affecting long-term total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
